Ravi K. R. Marreddy

Texas A&M Health Science Center — United States

Medicine · Health Sciences

11h-index500citations19works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Clostridium difficile and Clostridium perfringens research(9), Bacterial Genetics and Biotechnology(4), Antibiotic Resistance in Bacteria(4), RNA and protein synthesis mechanisms(4), Pharmacological Effects of Natural Compounds(4)

Publications19 total

Development of a high-throughput screening platform for <i>C. difficile</i> toxin synthesis inhibitors unveils meclizine as an antivirulence agent
Antimicrobial Agents and Chemotherapy·2025Open Access
Chemical genetic analysis of enoxolone inhibition of Clostridioides difficile toxin production reveals adenine deaminase and ATP synthase as antivirulence targets
Journal of Biological Chemistry·2024· 7 citedOpen Access
C. difficile intoxicates neurons and pericytes to drive neurogenic inflammation
Nature·2023· 54 citedOpen Access
The licorice metabolite enoxolone attenuates <i>Clostridioides difficile</i> pathophysiology by corrupting its metabolic and toxin production networks
2022Open Access
Ebselen Not Only Inhibits Clostridioides difficile Toxins but Displays Redox-Associated Cellular Killing
Microbiology Spectrum·2021· 13 citedOpen Access
Ebselen Exhibits Antimicrobial Activity Against <i>Clostridioides difficile</i> By Disrupting Redox Associated Metabolism
2020· 2 citedOpen Access
The early stage peptidoglycan biosynthesis Mur enzymes are antibacterial and antisporulation drug targets for recurrent Clostridioides difficile infection
Anaerobe·2019· 10 citedOpen Access
Small-Molecule Inhibition of the <i>C. difficile</i> FAS-II Enzyme, FabK, Results in Selective Activity
ACS Chemical Biology·2019· 12 citedOpen Access
The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for <i>Clostridium difficile</i> Infection
ACS Infectious Diseases·2018· 36 cited
New β-lactam – Tetramic acid hybrids show promising antibacterial activities
Bioorganic & Medicinal Chemistry Letters·2018· 14 cited
Solid-Phase Synthesis and Antibacterial Activity of Cyclohexapeptide Wollamide B Analogs
ACS Combinatorial Science·2018· 22 cited
Biophysical characterization of E. coli TolC interaction with the known blocker hexaamminecobalt
Biochimica et Biophysica Acta (BBA) - General Subjects·2017· 14 cited
Tripartite assembly of RND multidrug efflux pumps
Nature Communications·2016· 198 citedOpen Access
The Response of Lactococcus lactis to Membrane Protein Production
PLoS ONE·2011· 45 citedOpen Access
Efficient Overproduction of Membrane Proteins in Lactococcus lactis Requires the Cell Envelope Stress Sensor/Regulator Couple CesSR
PLoS ONE·2011· 27 citedOpen Access
Recombinant Membrane Protein Production: Past, Present and Future
2011· 3 cited
Amino Acid Accumulation Limits the Overexpression of Proteins in Lactococcus lactis
PLoS ONE·2010· 33 citedOpen Access
Beyond bottlenecks in membrane protein production
Data Archiving and Networked Services (DANS)·2010· 1 citedOpen Access
Human scFv SIgA expressed on <i>Lactococcus lactis</i> as a vector for the treatment of mucosal disease
Molecular Nutrition & Food Research·2008· 9 citedOpen Access

Frequent Co-authors

Julian G. Hurdle(11), Bert Poolman(4), Richard Lee(4), Min Dong(3), João P. C. Pinto(3), Eric R. Geertsma(3), Jan Kok(3), Dianqing Sun(3), Philip Cherian(3), Abiola Olumuyiwa Olaitan(3), Reid T. Powell(3), Clifford Stephan(3), Klaas M. Pos(2), Hjalmar P. Permentier(2), Oscar P. Kuipers(2), Xiaoqian Wu(2), Madhab Sapkota(2), Allan M. Prior(2), Jesse A. Jones(2), Kirk E. Hevener(2)